deficiency [1]. The absence of an accurate marker of
Introduction
cells with a decreased individual red cell haemoglobin concentration expressed as a percentage of the total The loss of response or resistance to eryhtropoietin number of red cells. %HRC has been reported to be ( EPO) therapy during the management of anaemia in a useful indicator of functional iron deficiency in end-stage renal failure is most commonly due to iron haemodialysis patients, with 2.5% being the upper limit of the normal range and greater than 10% The use of i.v. iron therapy is becoming common- Table 1 . Change in haemoglobin (g/dl ), serum ferritin (mg/l ) and % place in dialysis units. Intravenous iron is more expensred cell hypochromia over an 8-week period in response to IV iron ive than oral iron and its administration is not without saccharate (200 mg/week) in 82 maintenance haemodialysis patients potential hazard. We have investigated the utility of with persistent anaemia (Hb<10 g/dl ) and low serum ferritin percentage hypochromic red cells in haemodialysis (<100 mg/l ) patients that would be expected to respond to i.v. iron, that is those with a 'low' serum ferritin. The proportion of patients demonstrating a greater follow up period. All data are expressed as mean±standard than 0.5 g/dl and a greater than 1.0 g/dl increase in groups were made by ANOVA. The study protocol was approved by the local ethics committee.
Discussion Results
Oral iron therapy is cheap, easily available, and has been reported to provide sufficient quantities of iron Ninety-eight chronic haemodialysis patients received to maintain erythropoiesis during eryhtropoietin i.v. iron. Sixteen were excluded from analysis (13 therapy [7] . However, poor tolerance leading to nonreceived blood transfusion for symptomatic anaemia, compliance [8] and, in haemodialysis populations, two were transplanted prior to completing the study, chronic blood loss and interference with iron absorpand one patient had a possible anaphylactoid to the tion, may result in an inadequate iron supply. In a first dose of iron). No subject had abnormal Hb prospective, randomized study of 37 patients commenelectrophoresis nor an elevated random serum alumi-cing eryhtropoietin, there was no difference in the nium. In keeping with the protocol, i.v. iron was haemoglobin response with oral iron supplementation discontinued after 4 weeks in 37 patients.
(ferrous sulphate 200 mg tds) as compared to no iron Data from 82 patients were available for analysis supplementation, whilst those receiving i.v. iron dex- ( Table 1) . At baseline 71 were receiving erythropoietin and mean dose was 55.8±43.0 U/kg/week between 0 and 8 weeks in all groups, but the mean
The decision to discontinue i.v. iron if ferritin exceeded 250 mg/l resulted in a significant number of and may be associated with serious side effects, particularly anaphylaxis [10], cardiac toxicity, and susceptibil-patients stopping iron before the end of the study. It could be argued that this value of serum ferritin was ity to some infections [11] . These adverse effects have been reported with iron dextran, anaphylaxis in par-too low and that iron should have been continued until values exceeded 800-1000 mg/l. Some subjects ticular being associated with antibodies to dextran, rather than to the iron moeity. The identification of may therefore have remained iron deficient at this serum ferritin. However, values were equal between patients likely to respond to i.v. iron will both maximize haemoglobin response in EPO-treated patients and groups suggesting that this did not influence the results.
Intravenous iron was well tolerated, with a possible avoid potential side effects from unnecessary exposure.
The measurement of iron stores in haemodialysis adverse reaction in only one subject. This patient developed wheeze during the first few minutes of patients has been controversial. Serum iron, transferrin, and transferrin saturation show marked diurnal infusion. Prompt resolution followed the administration of hydrocortisone and chlorpheniramine. Low variation [12] and have a low specificity for diagnosing iron deficiency in haemodialysis patients [13, 14] . dose iron saccharate (10-40 mg i.v. bolus) has previously been reported to have a low incidence of side Serum ferritin reflects reticuloendothelial iron stores, but is also an acute phase reactant, increasing in a effects [18, 19] .
In summary we conclude that an increased % number of inflammatory/infective conditions. A low ferritin indicates absolute iron deficiency, but a normal hypochromic red cells predicts a greater likelihood and magnitude of response to i.v. iron therapy in maintenor high serum ferritin may be present in functional iron deficiency, where erythropoiesis is occurring too ance haemodialysis patients with a low serum ferritin.
Even so, 27% of patients with ∏3% hypochromic red rapidly to allow mobilization of stored iron. Modern automated technology allows measurement of indi-cells still responded. This test may be useful in directing iron therapy toward the patients most likely to benefit, vidual red cell haemoglobin concentration. The number of cells with a low haemoglobin (<28 g/dl ) can be thus maximising the risk5benefit ratio. It does not however identify all possible responders. expressed as a proportion of the total number of red cells, that is the percentage hypochromic red cells. This
